Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 479 full-time employees. The company went IPO on 2018-07-20. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Dr. Sushil Patel es el Chief Executive Officer de Replimune Group Inc, se unió a la empresa desde 2021.
¿Qué tal es el rendimiento del precio de la acción REPL?
El precio actual de REPL es de $7.2, ha aumentado un 3.15% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Replimune Group Inc?
Replimune Group Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Replimune Group Inc?
La capitalización bursátil actual de Replimune Group Inc es $594.5M
¿Es Replimune Group Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 9 analistas han realizado calificaciones de análisis para Replimune Group Inc, incluyendo 5 fuerte compra, 6 compra, 3 mantener, 0 venta, y 5 fuerte venta
